Cargando…
Blockade of leukemia inhibitory factor as a therapeutic approach to KRAS driven pancreatic cancer
KRAS mutations are present in over 90% of pancreatic ductal adenocarcinomas (PDAC), and drive their poor outcomes and failure to respond to targeted therapies. Here we show that Leukemia Inhibitory Factor (LIF) expression is induced specifically by oncogenic KRAS in PDAC and that LIF depletion by ge...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6624260/ https://www.ncbi.nlm.nih.gov/pubmed/31296870 http://dx.doi.org/10.1038/s41467-019-11044-9 |